1 of 9
eGenesis closed a $191M Series D financing led by Lux Capital in September.
Michelle Rose / Massachusetts General Hospital
Superluminal, led by CEO Cony D'Cruz, closed a $120M Series A investment.
Superluminal Medicines
MIT spinout Mantel, which uses 'molten salt' to capture carbon, announced the closing of its $30M series A round.
Mantel
AceUp, led by founders Will Foussier and Rohit Begani, is eyeing big customers after landing a $22.5M investment.
AceUp Inc.
Welcome back to our monthly roundup of the VC scene in Boston. We’ve left summer behind and are pushing full steam ahead into the fall. In August, the cumulative VC funding for Boston-area startups was $347 million, a noticeable dip from the rampant VC funding in July. In September we saw a return to form among local startups, with a total of $761.8 million from VC funds.
Read about all the September deals here, and be sure to sign up for The Beat, BostInno’s free daily innovation newsletter, so you never miss a thing.
- eGenesis, a Cambridge-based biotech company, closed a $191M Series D financing led by Lux Capital.
- CytoTronics, a Harvard spinout enabling the study of live cells, raised $13.5M in a seed extension.
- Six months after its initial raise, Boston-based Somite Therapeutics raised a $4.8M extension of its pre-seed round.
- All Hands AI, a Boston-based AI company, raised $5M in seed funding.
- Bambusa Therapeutics Inc., a Boston-based biotech, closed on a $15M seed financing round.
- Superluminal, a Boston-based biotech, closed a $120M Series A investment
- The MIT spinout Mantel, which uses 'molten salt' to capture carbon, announced the closing of its $30M series A round.
- Smartcat raised $43M in a Series C venture capital round led by new investor Left Lane Capital.
- AceUp, a Boston-based team coaching startup, is eyeing big customers after landing a $22.5M investment.
- “With,” the Israeli and Boston startup, announced $10M in VC for its community calendar AI
- Mirai Bio launched after about two years in development with an initial commitment of $50M from Flagship.
- Aktis Oncology, a Boston-based biotechnology company, announced the closing of an oversubscribed and upsized $175M Series B financing.
- 6K Inc. announced its $82M Series E funding round.
